Frazier Life Sciences

United States · Venture Capital & Private Equity

Frazier Life Sciences is a healthcare investment firm dedicated to advancing novel therapeutics through strategic funding and company creation. As a division of Frazier Healthcare Partners, established in 1991, it focuses on biopharmaceutical companies at all stages, from seed-stage startups to publicly traded entities. The firm aims to accelerate the development of innovative therapies for unmet medical needs. Frazier Life Sciences operates two main funds: venture funds that emphasize company creation and Series A/B investments, and public funds that invest over $1 billion in small- to mid-cap public biotech companies. The firm has formed over 30 companies since 2005 and raised $987 million for its latest venture fund in 2022. Its portfolio includes companies like Arcutis Biotherapeutics, which develops topical therapies for skin diseases, and ARMO BioSciences, known for its work in cancer immunotherapies. Frazier partners with biotech entrepreneurs and public companies to provide growth capital and strategic support.